0001415889-25-010983.txt : 20250417 0001415889-25-010983.hdr.sgml : 20250417 20250417185019 ACCESSION NUMBER: 0001415889-25-010983 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250415 FILED AS OF DATE: 20250417 DATE AS OF CHANGE: 20250417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kauh John Saewook M.D. CENTRAL INDEX KEY: 0002064881 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 25848824 MAIL ADDRESS: STREET 1: C/O TVARDI THERAPEUTICS, INC. STREET 2: 3 SUGAR CREEK CTR BLVD, STE 525 CITY: SUGAR LAND STATE: TX ZIP: 77478 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tvardi Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 SUGAR CREEK CTR. BLVD. STREET 2: STE 525 CITY: SUGAR LAND STATE: TX ZIP: 77478 BUSINESS PHONE: (713) 489-8654 MAIL ADDRESS: STREET 1: 3 SUGAR CREEK CTR. BLVD. STREET 2: STE 525 CITY: SUGAR LAND STATE: TX ZIP: 77478 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics, Inc. DATE OF NAME CHANGE: 20100721 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 4 1 form4-04172025_060415.xml X0508 4 2025-04-15 0001346830 Tvardi Therapeutics, Inc. TVRD 0002064881 Kauh John Saewook M.D. C/O TVARDI THERAPEUTICS, INC. 3 SUGAR CREEK CTR BLVD, STE 525 SUGAR LAND TX 77478 false true false false Chief Medical Officer 0 Employee Stock Option (right to buy) 6.12 2025-04-15 4 A 0 74049 A 2031-12-15 Common Stock 74049 74049 D 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Received in exchange for a stock option to acquire 552,129 shares of common stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") with the exercise price of $0.82 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. /s/ Dan Conn, Attorney- in-Fact 2025-04-17